OKYO Pharma Ltd (OKYO) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces Chairman and CEO Acquire Shares

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

LONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]